Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220254 · ClinicalTrials.gov registry record · NA
Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation
A NA study of Smoking Cessation and MindCotine Virtual Reality Mindful Exposure Therapy, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05220254: Completed NA study of Smoking Cessation and MindCotine Virtual Reality Mindful Exposure Therapy, sponsored by Stanford University.
NCT05220254 is a NA study of Smoking Cessation and MindCotine Virtual Reality Mindful Exposure Therapy that has completed, run by Stanford University. The registered enrollment target is 20 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05220254, a NA study of Smoking Cessation and MindCotine Virtual Reality Mindful Exposure Therapy, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to see how feasible a mobile app based virtual reality program for smoking cessation (MindCotine) would be among Stanford cancer center patients
Primary Outcome
Total number of patients who registered with the app, out of total number of participants who were enrolled (eligible and willing to accept help with quitting). This measure is to assess whether MindCotine is a feasible smoking cessation option among patients who smoke cigarettes.
Conditions Studied
Interventions
- BEHAVIORAL MindCotine's VR app
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2022-10-27 |
| Phase | NA |
What the finished NCT05220254 record still lists
NCT05220254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which MindCotine's VR app is the first listed.
NCT05220254 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05220254 about?
NCT05220254 is a clinical study titled "Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation". This study aims to see how feasible a mobile app based virtual reality program for smoking cessation (MindCotine) would be among Stanford cancer center patients
What is the current status of trial NCT05220254?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-10-18. Estimated completion is 2022-10-27.
What conditions does trial NCT05220254 study?
This clinical trial studies the following conditions: Smoking Cessation, MindCotine Virtual Reality Mindful Exposure Therapy.
What interventions are being tested in trial NCT05220254?
The interventions under investigation include: MindCotine's VR app (BEHAVIORAL).
Who is sponsoring clinical trial NCT05220254?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05220254 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05220254's enrollment target sits among peer trials
20 173rd of 188 higher than 10 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI